UNSPSC 51111742: Eribulin

This classification denotes a ketones and halichondrin b derivative and antimitotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LR24G6354G. European Medicines Agency schedules Eribulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31134. Eribulin generally arises in the molecular formula C40H59NO11.

The term ERIBULIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 1, 2008, list 59.) As of Q4 2014, ERIBULIN remains the US FDA Preferred Term for this commodity. Eribulin bears US NLM identifiers UMLS ID C2350866 and NCI Concept Code C96748. SMILES: CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O.

UNSPSC 51111742 Eribulin, a Commodity code, nominally identifies a specific chemotherapy agent, but recent state and local solicitations tagged with this code reveal a wider scope of pharmaceutical procurement spanning emergency response medications, pharmacy benefit management programs, and medical supplies for public health agencies. State and local governments are using this code to acquire naloxone kits for community health programs, establish direct-to-manufacturer prescription pathways, and source medical and first aid consumables for fire-rescue operations. The issuing bodies include county health departments, state health and human services agencies, municipal fire departments, and cooperative purchasing alliances. Seminole County, Florida, the City of Tampa, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have all issued solicitations under or near this taxonomy, suggesting that pharmaceutical procurement at the state and local level uses multiple code paths depending on product type and end use.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's multi-state footprint extending to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), the City of Tampa's sealed-bid procurement for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated value of $700,000.00 and responses due March 13, 2026, the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (response deadline April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026. The Tampa procurement includes a 5 percent SLBE bid discount (not to exceed $10,000) and requires SLBE participation tracking under the city's Equal Business Opportunity ordinance. MMCAP imposes a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation. Contract terms typically span one to two years with renewal or extension options.